
Giredestrant Plus Everolimus Wins FDA Approval in ESR1-Mutated Advanced Breast Cancer
Key Takeaways
- FDA-approved indication targets ESR1-mutated ER+/HER2− advanced disease after endocrine exposure, aligning selection with acquired resistance biology and necessitating contemporary molecular assessment at progression.
- evERA randomized 373 patients to giredestrant vs physician’s choice endocrine therapy, both with everolimus; the primary endpoint was investigator-assessed PFS per RECIST 1.1.
The FDA's decision comes weeks ahead of giredestrant's scheduled approval date.
The FDA approved giredestrant (Wilserdly; Genentech), an oral estrogen receptor (ER) antagonist, in combination with everolimus. It is approved for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer that recurred during or after endocrine-based adjuvant therapy or progressed on at least 1 endocrine-based regimen in the metastatic setting.
The approval came 4 weeks ahead of the FDA goal date. The application was reviewed under Project Orbis.
The Data
The approval is based on evERA Breast Cancer (NCT05306340), a randomized, open-label, multicenter trial that enrolled 373 adults, including 207 with ESR1-mutated tumors.
Patients were randomly assigned to giredestrant 30 mg daily (n = 183) or the physician’s choice of endocrine therapy (n = 190), which could be exemestane, fulvestrant, or tamoxifen. Both arms received everolimus 10 mg daily. Premenopausal and perimenopausal women also received a gonadotropin-releasing hormone (GnRH) agonist, as did men who had not undergone bilateral orchiectomy. The primary end point was investigator-assessed progression-free survival (PFS) per RECIST 1.1.
In the ESR1-mutated population, giredestrant plus everolimus reduced the risk of disease progression or death by 62% (HR, 0.38; 95% CI, 0.27 to 0.54). Median PFS was 10 months (95% CI, 8.1 to 12.9) with giredestrant vs 5.5 months (95% CI, 3.8 to 5.6) with standard endocrine therapy. The objective response rate nearly doubled, at 27% (95% CI, 18 to 37) vs 14% (95% CI, 8 to 22). Overall survival data were immature at the time of the PFS analysis.
What Pharmacists Should Watch
Because both arms received everolimus, much of the day-to-day toxicity burden will look familiar. The most common adverse reactions, occurring in at least 20% of patients, were stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea.
Counseling on stomatitis prevention and early pneumonitis recognition should happen before the first dose, not after symptoms appear. Laboratory abnormalities seen in at least 20% of patients were decreases in hemoglobin, lymphocytes, white blood cells, neutrophils, platelets, calcium, potassium, and sodium, along with increases in AST, ALT, and creatinine, so routine laboratory monitoring matters.
The label carries 2 warnings: bradycardia and embryo-fetal toxicity. Reasonable starting points are a baseline heart rate and a review for other medications that slow heart rate, along with confirming contraception plans for patients of reproductive potential. For premenopausal and perimenopausal women and for men, pharmacists should also confirm that GnRH agonist therapy is in place, as it was in the trial.
Testing is the other pressure point. ESR1 mutations often emerge during prior endocrine therapy, so a tumor profile from diagnosis may not reflect a patient’s current status. The liquid biopsy companion diagnostic gives care teams a practical way to retest at progression.
Giredestrant is dosed at 30 mg orally once daily, with or without food, until disease progression or unacceptable toxicity. Everolimus dosing should follow its own prescribing information, including its guidance on drug interactions.
Reference
FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer. FDA. November 16, 2026. Accessed November 16, 2026. https://www.fda.gov/drugs/cancer-approvals/fda-approves-giredestrant-combination-everolimus-er-positive-her2-negative-esr1-mutated-locally
Related to this article








